EyePoint - Public Comps and Valuation Multiples

EyePoint Overview

About EyePoint

EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Founded

2008

HQ

Employees

165

Website

eyepoint.bio

Sectors

Drug Development & Therapeutics
Drug Delivery Systems
BioTech

Financials

LTM Revenue $32.3M

LTM EBITDA -$230M

EV

$1.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

EyePoint Financials

As of November 2025, EyePoint reported last 12-month revenue of $32.3M and EBITDA of -$230M.

In the same period, EyePoint generated $30.2M in LTM gross profit and -$218M in net income.

See EyePoint valuation multiples based on analyst estimates

EyePoint P&L

In the most recent fiscal year, EyePoint reported revenue of $43.3M and EBITDA of -$129M.

EyePoint expects next 12-month revenue of XXX and NTM EBITDA of XXX

See EyePoint valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$32.3M	XXX	$43.3M	XXX	XXX	XXX
Gross Profit	$30.2M	XXX	$39.6M	XXX	XXX	XXX
Gross Margin	94%	XXX	91%	XXX	XXX	XXX
EBITDA	-$230M	XXX	-$129M	XXX	XXX	XXX
EBITDA Margin	-712%	XXX	-299%	XXX	XXX	XXX
EBIT	-$231M	XXX	-$146M	XXX	XXX	XXX
EBIT Margin	-714%	XXX	-337%	XXX	XXX	XXX
Net Profit	-$218M	XXX	-$131M	XXX	XXX	XXX
Net Margin	-674%	XXX	-302%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for EyePoint including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $32.3M. EBITDA for the last twelve months was -$230M. In the most recent fiscal year, EyePoint achieved $43.3M in revenue and -$129M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$32.3M	Analyst estimates available to subscribers	$43.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$30.2M	Analyst estimates available to subscribers	$39.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	93.6% gross margin	Analyst estimates available to subscribers	91.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$230M	Analyst estimates available to subscribers	-$129M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-712.4% EBITDA margin	Analyst estimates available to subscribers	-298.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$231M	Analyst estimates available to subscribers	-$146M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-713.5% EBIT margin	Analyst estimates available to subscribers	-337.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$218M	Analyst estimates available to subscribers	-$131M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-674.4% net profit margin	Analyst estimates available to subscribers	-302.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for EyePoint

This financial data table provides comprehensive performance metrics for EyePoint, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

EyePoint generated $32.3M in revenue over the last twelve months.
The company achieved -$230M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $30.2M.
Net income over the last twelve months reached -$218M.

Fiscal Year Performance

In the most recent fiscal year, EyePoint reported $43.3M in total revenue.
Fiscal year EBITDA was -$129M.
The company maintained a gross profit margin of 91.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was -298.6%.
Net profit margin reached -302.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for EyePoint. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

EyePoint Stock Performance

EyePoint has current market cap of $1.3B, and EV of $1.2B.

Market Cap Evolution

EyePoint Stock Data

As of December 12, 2025, EyePoint's stock price is $16.

See EyePoint trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.2B	$1.3B	XXX	XXX	XXX	XXX	$-2.99

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

EyePoint Valuation Multiples

EyePoint's trades at 26.6x EV/Revenue multiple, and -8.9x EV/EBITDA.

See valuation multiples for EyePoint and 15K+ public comps

EyePoint Financial Valuation Multiples

As of December 12, 2025, EyePoint has market cap of $1.3B and EV of $1.2B.

Equity research analysts estimate EyePoint's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

EyePoint has a P/E ratio of -6.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.3B	XXX	$1.3B	XXX	XXX	XXX
EV (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV/Revenue	35.6x	XXX	26.6x	XXX	XXX	XXX
EV/EBITDA	-5.0x	XXX	-8.9x	XXX	XXX	XXX
EV/EBIT	-5.0x	XXX	-7.9x	XXX	XXX	XXX
EV/Gross Profit	38.0x	XXX	n/a	XXX	XXX	XXX
P/E	-6.1x	XXX	-10.2x	XXX	XXX	XXX
EV/FCF	-10.2x	XXX	-8.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get EyePoint Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

EyePoint Margins & Growth Rates

EyePoint's last 12 month revenue growth is -71%

EyePoint's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.1M for the same period.

EyePoint's rule of 40 is -221% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

EyePoint's rule of X is -891% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for EyePoint and other 15K+ public comps

EyePoint Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-71%	XXX	-57%	XXX	XXX	XXX
EBITDA Margin	-712%	XXX	-299%	XXX	XXX	XXX
EBITDA Growth	49%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-221%	XXX	-370%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-891%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	307%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	428%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial